JP5719312B2 - デオキシアクタガルジン誘導体 - Google Patents

デオキシアクタガルジン誘導体 Download PDF

Info

Publication number
JP5719312B2
JP5719312B2 JP2011545788A JP2011545788A JP5719312B2 JP 5719312 B2 JP5719312 B2 JP 5719312B2 JP 2011545788 A JP2011545788 A JP 2011545788A JP 2011545788 A JP2011545788 A JP 2011545788A JP 5719312 B2 JP5719312 B2 JP 5719312B2
Authority
JP
Japan
Prior art keywords
compound
compounds
deoxyactagardine
treatment
present disclosure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011545788A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012515195A (ja
JP2012515195A5 (enExample
Inventor
ショールド ニコラース ワッドマン
ショールド ニコラース ワッドマン
Original Assignee
ノヴァクタ バイオシステムズ リミティッド
ノヴァクタ バイオシステムズ リミティッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノヴァクタ バイオシステムズ リミティッド, ノヴァクタ バイオシステムズ リミティッド filed Critical ノヴァクタ バイオシステムズ リミティッド
Publication of JP2012515195A publication Critical patent/JP2012515195A/ja
Publication of JP2012515195A5 publication Critical patent/JP2012515195A5/ja
Application granted granted Critical
Publication of JP5719312B2 publication Critical patent/JP5719312B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2011545788A 2009-01-14 2010-01-12 デオキシアクタガルジン誘導体 Expired - Fee Related JP5719312B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14449009P 2009-01-14 2009-01-14
US61/144,490 2009-01-14
PCT/GB2010/000042 WO2010082018A1 (en) 2009-01-14 2010-01-12 Deoxyactagardine derivatives

Publications (3)

Publication Number Publication Date
JP2012515195A JP2012515195A (ja) 2012-07-05
JP2012515195A5 JP2012515195A5 (enExample) 2013-03-07
JP5719312B2 true JP5719312B2 (ja) 2015-05-13

Family

ID=42110329

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011545788A Expired - Fee Related JP5719312B2 (ja) 2009-01-14 2010-01-12 デオキシアクタガルジン誘導体

Country Status (22)

Country Link
US (2) US8283371B2 (enExample)
EP (1) EP2387580B1 (enExample)
JP (1) JP5719312B2 (enExample)
KR (1) KR20110119699A (enExample)
CN (1) CN102348718B (enExample)
AU (1) AU2010205472B2 (enExample)
CA (1) CA2749278A1 (enExample)
DK (1) DK2387580T3 (enExample)
EA (1) EA021683B1 (enExample)
ES (1) ES2520165T3 (enExample)
HR (1) HRP20141084T1 (enExample)
IL (1) IL213927A0 (enExample)
MX (1) MX2011007313A (enExample)
NZ (1) NZ594011A (enExample)
PL (1) PL2387580T3 (enExample)
PT (1) PT2387580E (enExample)
RS (1) RS53586B1 (enExample)
SG (1) SG172944A1 (enExample)
SI (1) SI2387580T1 (enExample)
TW (1) TWI453029B (enExample)
WO (1) WO2010082018A1 (enExample)
ZA (1) ZA201104991B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0600928D0 (en) 2006-01-17 2006-02-22 Novacta Biosystems Ltd Improvements relating to lantibiotics
GB0714029D0 (en) * 2007-07-18 2007-08-29 Novacta Biosystems Ltd Lantibiotic-based compounds having antimicrobial activity
GB0714030D0 (en) * 2007-07-18 2007-08-29 Novacta Biosystems Ltd The use of type-B lantibiotic-based compounds having antimicrobial activity
NZ594011A (en) 2009-01-14 2013-12-20 Novacta Biosystems Ltd Deoxyactagardine derivatives
KR20110122139A (ko) 2009-02-04 2011-11-09 노박타 바이오시스템스 리미티드 액타가르딘 유도체
WO2011061748A1 (en) * 2009-11-19 2011-05-26 Strides Arcolab Limited Rifaximin premix
GB201001688D0 (en) 2010-02-02 2010-03-17 Novacta Biosystems Ltd Compounds
GB201013513D0 (en) * 2010-08-11 2010-09-22 Novacta Biosystems Ltd Formulations
GB201013507D0 (en) * 2010-08-11 2010-09-22 Novacta Biosystems Ltd Compounds
GB201013509D0 (en) * 2010-08-11 2010-09-22 Novacta Biosystems Ltd Compounds
GB201013508D0 (en) * 2010-08-11 2010-09-22 Novacta Biosystems Ltd Compounds
GB201213434D0 (en) 2012-07-27 2012-09-12 Novacta Biosystems Ltd The use of type-B lantibiotic-based compounds having antimicrobial activity

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
GB8507528D0 (en) * 1985-03-22 1985-05-01 Lepetit Spa Basis monocarboxyamide derivatives
US5304540A (en) 1988-06-22 1994-04-19 Applied Microbiology, Inc. Pharmaceutical bacteriocin compositions and methods for using the same
IN167138B (enExample) 1988-08-17 1990-09-01 Hoechst India
GB8926639D0 (en) 1989-11-24 1990-01-17 Agricultural & Food Res Delayed release formulations
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
IT1260505B (it) 1992-06-01 1996-04-09 Poli Ind Chimica Spa Sistemi farmaceutici orali a cessione ritardata per il rilascio specifico nel colon
IL107887A (en) 1992-12-08 2003-07-06 Ambi Inc Stabilized lanthionine containing bacteriocin compositions
US5512269A (en) 1993-06-09 1996-04-30 Burroughs Wellcome, Co. Method of treating retained pulmonary secretions
PT700998E (pt) 1994-09-12 2004-03-31 Aventis Pharma Gmbh Mersacidina recombinante e metodo para a sua producao
BR9609281A (pt) 1995-06-23 1999-06-15 Ambi Inc Método para o controle de bactérias gram-positivas resistentes a antibióticos e tratamento de infecções
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US5985823A (en) 1997-06-09 1999-11-16 Ambi Inc. Method for the treatment of diarrheal disease and for eliminating particular bacterial populations from the colon
US5958873A (en) 1997-06-09 1999-09-28 University Of Cincinnati Oral formulation for treatment of bacteria-induced diseases of the colon
DE19745583A1 (de) 1997-10-15 1999-04-22 Hoechst Marion Roussel De Gmbh Neues Lantibiotikum verwandt mit Actagardine, Verfahren zur Herstellung und Verwendung derselben
US6569830B1 (en) 1999-03-05 2003-05-27 Ambi, Inc. Compositions and methods for treatment of staphylococcal infection while suppressing formation of antibiotic-resistant strains
JP4188078B2 (ja) 2000-06-28 2008-11-26 スミスクライン ビーチャム ピー エル シー 湿式粉砕法
GB0110432D0 (en) 2001-04-27 2001-06-20 Plant Bioscience Ltd Lantibiotic production
WO2002103010A1 (en) 2001-06-14 2002-12-27 Plant Bioscience Limited Methods and materials for targeted gene disruption in actinomycete bacteria
US6861236B2 (en) 2002-05-24 2005-03-01 Applied Nanosystems B.V. Export and modification of (poly)peptides in the lantibiotic way
US7199230B2 (en) 2002-10-10 2007-04-03 Molichem Medicines, Inc. Nucleic acids encoding duramycin
US7351687B2 (en) 2003-07-18 2008-04-01 Vicuron Pharmaceuticals, Inc. Antibiotic 107891, its factors A1 and A2, pharmaceutically acceptable salts and compositions, and use thereof
MXPA06000691A (es) 2003-07-18 2006-04-11 Vicuron Pharm Inc Antibiotico 107891, sus factores a1 y a2, sales y composiciones farmaceuticamente aceptables y uso de las mismas.
GB0406870D0 (en) 2004-03-26 2004-04-28 Novacta Biosystems Ltd Improvements relating to the production of lantibiotics
JP2009509519A (ja) 2005-09-27 2009-03-12 ノヴァクタ バイオシステムズ リミティッド ランチビオティックメルサシジンの変種およびそれらの使用
GB0600928D0 (en) 2006-01-17 2006-02-22 Novacta Biosystems Ltd Improvements relating to lantibiotics
WO2008050209A1 (en) 2006-10-27 2008-05-02 Pfizer Products Inc. Hydroxypropyl methyl cellulose hard capsules and process of manufacture
CA2690267A1 (en) 2007-06-12 2008-12-18 The University Of British Columbia Small cationic antimicrobial peptides
GB0714029D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd Lantibiotic-based compounds having antimicrobial activity
GB0714030D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd The use of type-B lantibiotic-based compounds having antimicrobial activity
KR20110086582A (ko) 2008-11-24 2011-07-28 센티넬라 파마세티컬즈, 인크. 항균활성이 강화된 란티바이오틱 카르복시아미드 유도체
GB0900599D0 (en) 2009-01-14 2009-02-18 Novacta Biosystems Ltd Treatment
NZ594011A (en) 2009-01-14 2013-12-20 Novacta Biosystems Ltd Deoxyactagardine derivatives
KR20110122139A (ko) 2009-02-04 2011-11-09 노박타 바이오시스템스 리미티드 액타가르딘 유도체

Also Published As

Publication number Publication date
PT2387580E (pt) 2014-10-30
JP2012515195A (ja) 2012-07-05
SI2387580T1 (sl) 2014-11-28
CN102348718A (zh) 2012-02-08
KR20110119699A (ko) 2011-11-02
EP2387580A1 (en) 2011-11-23
ES2520165T3 (es) 2014-11-11
ZA201104991B (en) 2013-10-31
CN102348718B (zh) 2015-06-03
WO2010082018A1 (en) 2010-07-22
CA2749278A1 (en) 2010-07-22
US8741945B2 (en) 2014-06-03
MX2011007313A (es) 2011-08-04
TW201029661A (en) 2010-08-16
US20100179207A1 (en) 2010-07-15
DK2387580T3 (da) 2014-10-13
NZ594011A (en) 2013-12-20
EP2387580B1 (en) 2014-08-13
HRP20141084T1 (hr) 2015-02-13
US20120277145A1 (en) 2012-11-01
IL213927A0 (en) 2011-07-31
EA021683B1 (ru) 2015-08-31
EA201190071A1 (ru) 2012-06-29
SG172944A1 (en) 2011-08-29
AU2010205472B2 (en) 2013-03-14
US8283371B2 (en) 2012-10-09
AU2010205472A1 (en) 2011-07-28
RS53586B1 (sr) 2015-02-27
PL2387580T3 (pl) 2015-01-30
TWI453029B (zh) 2014-09-21

Similar Documents

Publication Publication Date Title
JP5719312B2 (ja) デオキシアクタガルジン誘導体
EA024792B1 (ru) Производные полимиксина
JP5731407B2 (ja) アクタガルジン誘導体
WO2013186384A1 (en) N-substituted second generation derivatives of antifungal antibiotic amphotericin b and methods of their preparation and application
US20240165245A1 (en) Multivalent peptoid oligomers, pharmaceutical compositions and methods of using same
WO2010082019A1 (en) Actagardine derivatives, and pharmaceutical use thereof
US20090264345A1 (en) Macrocyclic peptides and methods for making and using them
WO2007109620A2 (en) Macrocyclic peptides and methods for making and using them
TW202348604A (zh) 作為組蛋白去乙醯酶抑制劑之巨環硫酯前藥
CN101153053B (zh) 骨生肽、其制备方法和其药物组合物与用途
CA2379851A1 (en) Pseudomycin n-acyl side-chain analogs
CN109415378B (zh) 水溶性Epothilone衍生物及其制备方法
US20250011366A1 (en) Prodrugs of Antibiotic Teixobactin
CN111690040A (zh) 多粘菌素衍生物、其制备方法和应用
CN102838661A (zh) 万古霉素或去甲万古霉素类似物及其药用用途
WO2017193757A1 (zh) 水溶性Epothilone衍生物及其制备方法
WO2012020220A1 (en) Compounds
JP2003505399A (ja) プソイドマイシンのアミドおよびエステルアナログ

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130111

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130111

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140630

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140925

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150302

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150320

R150 Certificate of patent or registration of utility model

Ref document number: 5719312

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees